Abdulhamied Alfaddagh

Abdulhamied Alfaddagh

Auto-generated profile, based on publicly available information

Abdulhamied Alfaddagh

Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
SMSeth S. Martin
Seth S. Martin
TLThorsten M. Leucker
Thorsten M. Leucker
EMErin D. Michos
Erin D. Michos
MBMichael J. Blaha
Michael J. Blaha
PMPeter Paul MD
Peter Paul MD
Inflammation constitutes a complex, highly conserved cascade of molecular and cellular events. Inflammation has been labeled as “the fire within,” is highly regulated, and is critical to host defense and tissue repair. In general, inflammation is beneficial and has evolved to promote survival. However, inflammation can also be maladaptive when chronically activated and sustained, leading to progressive tissue injury and reduced survival. Examples of a maladaptive response include rheumatologic disease and atherosclerosis. Despite evidence gathered by Virchow over 100 years ago showing that inflammatory white cells play a role in atherogenesis, atherosclerosis was until recently viewed as a disease of passive cholesterol accumulation in the subendothelial space. This view has been supplanted by considerable basic scientific and clinical evidence demonstrating that every step of atherogenesis, from the development of endothelial cell dysfunction to foam cell formation, plaque formation and progression, and ultimately plaque rupture stemming from architectural instability, is driven by the cytokines, interleukins, and cellular constituents of the inflammatory response. Herein we provide an overview of the role of inflammation in atherosclerotic cardiovascular disease, discuss the predictive value of various biomarkers involved in inflammation, and summarize recent clinical trials that evaluated the capacity of various pharmacologic interventions to attenuate the intensity of inflammation and impact risk for acute cardiovascular events.

1 January 2016 in Translational Research
Verified
Journal Article
Closed access
FWFrancine K. Welty
Francine K. Welty
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
TETarec K. Elajami
Tarec K. Elajami

2 December 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
TETarec K. Elajami
Tarec K. Elajami
HAHasan Ashfaque
Hasan Ashfaque
MSMohamad Saleh
Mohamad Saleh
BBBruce R. Bistrian
Bruce R. Bistrian
FWFrancine K. Welty
Francine K. Welty
Background: Although statins reduce cardiovascular events, residual risk remains. Therefore, additional modalities are needed to reduce risk. We evaluated the effect of eicosapentaenoic acid and docosahexaenoic acid in pharmacologic doses added to statin treatment on coronary artery plaque volume. Methods and Results: A total of 285 subjects with stable coronary artery disease on statins were randomized to omega‐3 ethyl‐ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily) or no omega‐3 (control) for 30 months. Coronary plaque volume was assessed by coronary computed tomographic angiography. Mean ( SD ) age was 63.0 (7.7) years; mean low‐density lipoprotein cholesterol ≤80 mg/dL. In the intention‐to‐treat analysis, our primary endpoint, noncalcified plaque volume, was not different between groups ( P =0.14) but approached significance in the per protocol analysis ( P =0.07). When stratified by age in the intention‐to‐treat analysis, younger omega‐3 subjects had significantly less progression of the primary endpoint, noncalcified plaque ( P =0.013), and fibrous, calcified and total plaque. In plaque subtype analysis, controls had significant progression of fibrous plaque compared to no change in the omega‐3 ethyl‐ester group (median % change [interquartile range], 5.0% [−5.7, 20.0] versus −0.1% [−12.3, 14.5], respectively; P =0.018). Among those on low‐intensity statins, omega‐3 ethyl‐ester subjects had attenuation of fibrous plaque progression compared to controls (median % change [interquartile range], 0.3% [−12.8, 9.0] versus 4.8% [−5.1, 19.0], respectively; P =0.032). In contrast, those on high‐intensity statins had no difference in plaque change in either treatment arm. Conclusions: High‐dose eicosapentaenoic acid and docosahexaenoic acid provided additional benefit to statins in preventing progression of fibrous coronary plaque in subjects adherent to therapy with well‐controlled low‐density lipoprotein cholesterol levels. The benefit on low‐intensity statin, but not high‐intensity statin, suggests that statin intensity affects plaque volume. Clinical Trial Registration: URL : http://www.ClinicalTrials.gov . Unique identifier: NCT 01624727.

1 July 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TETarec K. Elajami
Tarec K. Elajami
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
DLDharshan Lakshminarayan
Dharshan Lakshminarayan
MSMichael Soliman
Michael Soliman
MCMadhuri Chandnani
Madhuri Chandnani
FWFrancine K. Welty
Francine K. Welty
Background: Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ) supplementation attenuates progression of albuminuria in subjects with coronary artery disease. Methods and Results: Two‐hundred sixty‐two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin‐to‐creatinine ratio ( ACR ) was compared. Mean ( SD ) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% ( P <0.001) in diabetic subjects not receiving Lovaza, whereas those receiving Lovaza had no change. In diabetic subjects on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker, those receiving Lovaza had no change in urine ACR , whereas those not receiving Lovaza had a 64.2% increase ( P <0.001). Change in ACR was directly correlated with change in systolic blood pressure ( r =0.394, P =0.01). Conclusions: EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin‐converting enzyme‐inhibitor or angiotensin‐receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01624727.

1 June 2019 in Atherosclerosis
Verified
Journal Article
Closed access
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
TETarec K. Elajami
Tarec K. Elajami
MSMohamad Saleh
Mohamad Saleh
DMDonya Mohebali
Donya Mohebali
BBBruce R. Bistrian
Bruce R. Bistrian
FWFrancine K. Welty
Francine K. Welty

1 July 2018 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
AAAbdulhamied Alfaddagh
Abdulhamied Alfaddagh
TETarec K. Elajami
Tarec K. Elajami
MSMohamad Saleh
Mohamad Saleh
MEMohamad Elajami
Mohamad Elajami
BBBruce R. Bistrian
Bruce R. Bistrian
FWFrancine K. Welty
Francine K. Welty